HT
LXRX icon

Headlands Technologies’s Lexicon Pharmaceuticals LXRX Stock Holding History

Headlands Technologies’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$298K Buy
191,322
+55,209
+41% +$80.3K 0.03% 502
2025
Q4 		$157K Buy
136,113
+86,466
+174% +$119K 0.01% 609
2025
Q3 		$67K Buy
+49,647
New +$56.3K 0.01% 584
2024
Q1 		– Sell
-204
Closed -$312 – 1424
2023
Q4 		$312 Buy
+204
New +$243 ﹤0.01% 913

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Headlands Technologies's LXRX Position: Q1 2026 in Review

Headlands Technologies increased its Lexicon Pharmaceuticals (LXRX) stake by 41% in Q1 2026, buying an estimated $80.3K and bringing the position to 191,322 shares worth $298K. The position accounts for 0.03% of the portfolio, ranked #502.

Headlands Technologies first reported a position in LXRX in Q4 2023 and has held it in 4 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Headlands Technologies held 191,322 shares of Lexicon Pharmaceuticals worth $298K as of Q1 2026.
  • Headlands Technologies bought 55,209 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $80.3K.
  • Lexicon Pharmaceuticals made up 0.03% of Headlands Technologies's portfolio in Q1 2026, its #502 holding.
  • Headlands Technologies first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.